Why Did Piper Sandler Give Intra-Cellular Therapies Inc (ITCI) Stock Overweight Rating?
Intra-Cellular Therapies Inc (ITCI) stock saw a modest uptick, ending the day at $126.5 which represents a slight increase of $0.30 or 0.24% from the prior close of $126.2. The stock opened at $126.64 and touched a low of $126.
Zoetis Inc remains a standout in the struggling animal health sector, benefiting from its pricing power and portfolio of irreplaceable therapeutics, according to a Piper Sandler survey.
That's changed: Lyons is acknowledged heir apparent at a giant fintech where he'll become CEO by July at the latest.
In a report released today, Arvind Ramnani from Piper Sandler maintained a Hold rating on PayPal Holdings (PYPL – Research Report), with a ...
Pets insurance company Trupanion (NASDAQ:TRUP) was upgraded at Piper Sandler on improving investor sentiment and several ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 14.59% ...
Piper Sandler analyst Anna Andreeva maintained a Hold rating on Deckers Outdoor (DECK – Research Report) today and set a price target of ...
Tesla remains the “top buy-and-hold” stock for analysts at Piper Sandler, who massively raised their price target for the ...
LONDON, January 06, 2025--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of Paul Leece, Jeremi Martin and Daniel Allmomen to its energy ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Piper Sandler analyst Michael Lavery maintained a Buy rating on PepsiCo (PEP – Research Report) today and set a price target of $171.00. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback